What Sermorelin is
Sermorelin is a growth hormone releasing hormone analog used to stimulate endogenous GH-axis signaling rather than delivering growth hormone directly.
Sermorelin is grouped under Fitness + Recovery / Longevity + Skin on PeptideFactCheck because it remains one of the main comparison points for people looking at GH-axis peptides without jumping straight to exogenous growth hormone.
The useful starting point is to separate the molecule itself from the internet story around it. It remains one of the main comparison points for people looking at GH-axis peptides without jumping straight to exogenous growth hormone.
Why people keep looking it up
It remains one of the main comparison points for people looking at GH-axis peptides without jumping straight to exogenous growth hormone.
Sermorelin is a growth hormone releasing hormone analog used to stimulate endogenous GH-axis signaling rather than delivering growth hormone directly.
Sermorelin tends to stay in the conversation because it touches a familiar public theme: ghrh analog, gh axis, and pituitary signaling. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
There is real human endocrine literature, but online anti-aging narratives run broader than the evidence.
Human endocrine data exists for GH-axis effects, but optimization claims around recovery, physique, or longevity need tighter outcome evidence.
Mechanistic support comes from GHRH receptor pharmacology and pituitary hormone-release signaling.
Why this page carries the current tier: There is real human endocrine literature, but online anti-aging narratives run broader than the evidence.
The current seed trail for Sermorelin is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.
Safety, limits, and regulatory context
GH-axis manipulation still carries endocrine uncertainty, especially around glucose, edema-like effects, and long-term off-label use.
Older clinical and compounding history exists, but current FDA approval and compounding status should be checked against official sources before making market claims.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Sermorelin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Sermorelin is CID 16132413. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16132413
- Formula
- C149H246N44O42S
- Molecular weight
- 3357.9
- InChIKey
- WGWPRVFKDLAUQJ-MITYVQBRSA-N
Matched synonyms include SERMORELIN, Sermorelina, 86168-78-7, Sermoreline, Sermorelinum, DTXSID70903978, 89243S03TE, TYR-ALA-ASP-ALA-ILE-PHE-THR-ASN-SER-TYR-ARG-LYS-VAL-LEU-GLY-GLN-LEU-SER-ALA-ARG-LYS-LEU-LEU-GLN-ASP-ILE-MET-SER-ARG-NH2.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Sermorelin returns 27 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Sermorelin returns 442 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.